Action 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Marché Fermé - Japan Exchange
Autres places de cotation
 08:00:00 13/06/2024 		Varia. 5j. Varia. 1 janv.
4 138 JPY -0,65% Graphique intraday de Takeda Pharmaceutical Company Limited -1,55% +2,07%
06/06 L'unité pharmaceutique de Takeda s'associe à HEALWELL AI pour l'analyse des données réelles sur l'œdème angioneurotique héréditaire MT
06/06 Torrent Pharma signe un accord avec le japonais Takeda pour commercialiser un médicament contre les troubles liés à l'acidité en Inde MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen
TAKEDA PHARMACEUTICAL : Form 6 K
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
Former Takeda Employee Pleads Guilty to Defrauding Company
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
GSK blood cancer drug nearly halves risk of death in late-stage trial
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM
Takeda Gets CHMP Approval for Recombinant ADAMTS13
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4502
  4. Actualités Takeda Pharmaceutical Company Limited
  5. Autres langues